Physician profile
Fariba Javaherian
NPI 1114088804
$759.02
in general payments reported to CMS, 2019-2025
9 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2021: $219 · 2022: $21.26 · 2024: $31.76 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $309.90 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $124.96 | 2025 | Fanapt |
| Amarin Pharma, INC. | $121.08 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.01 | 2019 | |
| Amgen INC. | $31.76 | 2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $23.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.54 | 2021 | |
| Kvk-Tech, INC. | $16.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariba Javaherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.